论文部分内容阅读
目的:观察前列地尔联合低分子肝素治疗高原性心脏病肺动脉高压的疗效。方法:将48例高原性心脏病肺动脉高压患者随机分为两组,对照组26例,予常规治疗;治疗组22例,予常规治疗基础上加用前列地尔及低分子肝素,连续1周。两组治疗前后行心脏彩超和血液流变学检查。结果:治疗组治疗后肺动脉高压、全血黏度、红细胞聚集指数较治疗前明显降低,对照组治疗后无明显变化,两组治疗后比较有显著差异。结论:前列地尔联合低分子肝素治疗高原性心脏病肺动脉高压,可显著降低肺动脉高压和血黏度。
Objective: To observe the curative effect of alprostadil combined with low molecular weight heparin on pulmonary hypertension in patients with high altitude heart disease. Methods: Forty-eight patients with pulmonary heart disease complicated with heart disease were randomly divided into two groups, control group (n = 26) and routine treatment. The treatment group (n = 22) received alprostadil and low molecular weight heparin for 1 week . The two groups before and after the treatment of cardiac ultrasound and hemorheology. Results: After treatment, pulmonary hypertension, whole blood viscosity and erythrocyte aggregation index in the treatment group were significantly lower than those before treatment, while there was no significant change in the control group after treatment. There was significant difference between the two groups after treatment. Conclusion: Alprostadil combined with low molecular weight heparin in treatment of pulmonary heart disease patients with high altitude heart disease can significantly reduce pulmonary hypertension and blood viscosity.